Low-Compared with High-Dose Regimen of Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: A Systematic Review and Meta-analysis

Abstract

Introduction

International recommendation supports induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) as a new standard of care for locally advanced nasopharyngeal cancer (LA-NPC) which give a survival benefit. TPF is one of the IC regimens which consists of docetaxel (75 mg/m², 1 hour infusion), cisplatin (75 mg/m², 0.5–3 hours), and 5-fluorouracil (600 mg/m², 4 days). Previous retrospective study in Chinese population reported low-dose TPF (L-TPF), consists of docetaxel (60 mg/m²), cisplatin (65 mg/m²), and then 5-fluorouracil (550 mg/m²/d; 5 days), showed better tolerance and compliance rates, with similar efficacy to high-dose TPF (H-TPF). Thus, we aim to evaluate the current evidence of the effect of L-TPF compared with H-TPF on survival and tolerance as IC in LA-NPC.

Methods

Data were collected from PubMed, PubMed Central, and Science Direct, using combinations of keywords related to neoadjuvant chemotherapy (NAC) or IC, TPF dose regimen, and LA-NPC. The included studies investigated the efficacy and toxicity of IC with a TPF regimen. The quality of each included study was assessed using the Newcastle–Ottawa scale for cohort studies and the JADAD scale for randomized controlled trial (RCT). Only moderate- and good-quality studies were further evaluated in the meta-analysis.

Results

A total of six studies consisting of 509 NAC patients were included. All the studies evaluated overall survival (OS) and progression-free survival (PFS). Quantitative analysis showed that L-TPF + CCRT significantly showed good OS (hazard ratio [HR] = 0.50; 95% confidence interval [CI], 0.33–0.76; p = 0.001) but not PFS (HR = 0.45; 95% CI, 0.16–1.25; p = 0.13). Common chemotoxicities that were found in both groups were neutropenia and anemia.

Conclusion

L-TPF IC had a significant positive effect on the survival of LA-NPC patients. Further, larger multicenter RCT studies are needed to focus on evaluating the optimal TPF regimen dose in LA-NPC.

Keywords

chemotherapy - dose - induction chemotherapy - nasopharyngeal cancer - survival - toxicity

Publication History

Received: 29 March 2024

Accepted: 26 July 2024

Article published online:
23 August 2024

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GlOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 2 Mao YP, Xie FY, Liu LZ. et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009; 73 (05) 1326-1334
• 3 Blanchard P, Lee A, Marguet S. et al; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015; 16 (06) 645-655
• 4 Li WF, Chen NY, Zhang N. et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer 2019; 145 (01) 295-305
• 5 Liang ZG, Zhu XD, Tan AH. et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: meta-analysis of 1,096 patients from 11 randomized controlled trials. Asian Pac J Cancer Prev 2013; 14 (01) 515-521
• 6 Zhou R, Zhu J, Chen X, Liu Y, Wang Y, Zhang T. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Clin Transl Oncol 2020; 22 (03) 429-439
• 7 Wu LR, Liu YT, Jiang N. et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center. Oral Oncol 2017; 69: 26-32
• 8 Chua DTT, Ma J, Sham JST. et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23 (06) 1118-1124
• 9 Sun Y, Li WF, Chen NY. et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17 (11) 1509-1520
• 10 Jin T, Zhang Q, Jiang F. et al. Neoadjuvant chemotherapy with different dose regimens of docetaxel, cisplatin and fluorouracil (TPF) for locoregionally advanced nasopharyngeal carcinoma: a retrospective study. Oncotarget 2017; 8 (59) 100764-100772
• 11 Lo CKL, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol 2014; 14 (01) 45
• 12 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
• 13 Definition of overall survival-NCI dictionary of cancer terms; national cancer Institute (Internet). Accessed July 14, 2020 at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival
• 14 Definition of progression-free survival- NCI dictionary of cancer terms- National cancer institute (Internet). Accessed July 14, 2020 at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/progression-free-survival
• 15 Ghom AG, Mhaske S. Textbook of Oral Pathology. 2nd ed.. India: Jaypee Brothers, Medical Publishers Pvt. Limited; 2013: 1025
• 16 Augestad KM, Berntsen G, Lassen K, Bellika JG, Wootton R, Lindsetmo RO. Study Group of Research Quality in Medical Informatics and Decision Support (SQUID). Standards for reporting randomized controlled trials in medical informatics: a systematic review of CONSORT adherence in RCTs on clinical decision support. J Am Med Inform Assoc 2012; 19 (01) 13-21
• 17 Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8 (01) 16
• 18 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
• 19 Kawahira M, Yokota T, Hamauchi S. et al. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3. Jpn J Clin Oncol 2017; 47 (08) 705-712
• 20 Zhu J, Duan B, Shi H. et al. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol 2019; 97: 37-43
• 21 Ou D, Blanchard P, El Khoury C. et al. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncol 2016; 62: 114-121
• 22 Frikha M, Auperin A, Tao Y. et al; GORTEC. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol 2018; 29 (03) 731-736
• 23 Mohamad I, Abu-Hijleh F, Mayta E. et al. Comparison of two standard treatment approached in locoregionanly advanced nasopharyngeal carcinoma. South Asian J Cancer 2022; 11 (03) 223-228
• 24 Lee AWM, Tung SY, Ngan RKC. et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer 2011; 47 (05) 656-666
• 25 Loong HH, Ma BBY, Leung SF. et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 2012; 104 (03) 300-304